We report the case of a patient treated with dabrafenib and trametinib (mitogen-activated protein kinase pathway inhibitors) for stage 3b cutaneous melanoma who developed bilateral uveitis. Although there have been reports of ocular side effects with this class of drugs, uveitis has not been previously reported to the best of our knowledge. This case indicates the wide range of side effects that can be seen with the newer targeted biological therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901607 | PMC |
| http://dx.doi.org/10.1159/000357060 | DOI Listing |
Publication Analysis
Top Keywords
kinase pathway
8
side effects
8
uveitis result
4
result map
4
map kinase
4
pathway inhibition
4
inhibition report
4
report case
4
case patient
4
patient treated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!